Glycomimetics announced results from its Phase 1/2 study of GMI-1070 for the treatment of sickle cell disease.  In particular, Glycomimetics highlighted clinical study data showing the effects of GMI-1070 on certain key biomarkers and on the activation state of leukocytes (white blood cells), as well as the safety and pharmacokinetics of the drug.

GMI-1070 is a rationally-designed glycomimetic inhibitor of E-, P- and L-selectins, and inhibits a key early step in the inflammatory process leading to leukocyte adhesion and recruitment to inflamed tissue.

For more information call (240) 243-1201 or visit